# Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

> **NCT00126893** · PHASE1 · TERMINATED · sponsor: **Celgene Corporation** · enrollment: 36 (—)

## Conditions studied

- Myeloid Leukemia

## Interventions

- **DRUG:** CC-401

## Key facts

- **NCT ID:** NCT00126893
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 36 (—)
- **Last updated:** 2007-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126893, "Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00126893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*